Hana Biosciences to Present at the 8th Annual BIO CEO & Investor Conference
February 07 2006 - 7:27AM
Business Wire
Hana Biosciences (AMEX:HBX), a biopharmaceutical company focused on
advancing cancer care, will present at the 8th Annual BIO CEO &
Investor Conference, on Tuesday, February 14, 2006 at 3:00 PM EST.
The presentation will take place in the Basildon Room at the
Waldorf Astoria Hotel on 301 Park Avenue, New York, New York. Mark
Ahn, PhD, President and CEO of Hana Biosciences, will provide a
comprehensive company overview including an update on recent
corporate and scientific developments. A live audio webcast of the
presentation can be accessed on the investor relations page of the
company's website, www.hanabiosciences.com. An audio replay of the
presentation will also be available for 90 days after the
conference. About Hana Biosciences Hana Biosciences, Inc.
(AMEX:HBX) is a South San Francisco, CA-based biopharmaceutical
company that acquires, develops, and commercializes innovative
products to advance cancer care. The company is committed to
creating value by building a world-class team, accelerating the
development of lead product candidates, expanding its pipeline by
being the alliance partner of choice, and nurturing a unique
company culture. Additional information on Hana Biosciences can be
found at www.hanabiosciences.com. This press release contains
forward-looking statements that involve risks and uncertainties
that could cause Hana's actual results to differ materially from
the anticipated results and expectations expressed in these
forward-looking statements. These statements are based on current
expectations, forecasts and assumptions that are subject to risks
and uncertainties, which could cause actual outcomes and results to
differ materially from these statements. Among other things, there
can be no assurances that any of Hana's development efforts
relating to its product candidates will be successful. Other risks
that may affect forward-looking information contained in this press
release include the possibility of being unable to obtain
regulatory approval of Hana's product candidates, the risk that the
results of clinical trials may not support Hana's claims, Hana's
reliance on third party researchers to develop its product
candidates and its lack of experience in developing pharmaceutical
products. Additional risks are described in the company's Annual
Report on Form 10-KSB for the year ended December 31, 2004. Hana
assumes no obligation to update these forward-looking statements,
except as required by law.
Hana Biosciences (AMEX:HBX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hana Biosciences (AMEX:HBX)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Hana Biosciences (American Stock Exchange): 0 recent articles
More Hana Biosciences News Articles